Opaleye Management Inc., Opaleye, L.P., and James Silverman filed an amended beneficial ownership statement with the SEC on November 6, 2026, disclosing that as of September 30, 2026, they collectively held zero shares of Pasithea Therapeutics Corp. common stock.

Key Highlights

  • Three reporting persons: Opaleye Management Inc. (Massachusetts investment adviser), Opaleye, L.P. (Delaware limited partnership), and James Silverman filed jointly as Amendment No. 2.
  • Zero beneficial ownership: Each reporting person reported 0 shares beneficially owned, with 0% of the class, as of September 30, 2026.
  • No voting or dispositive power: All sole and shared voting power and sole and shared dispositive power figures were each reported as 0.00 for every reporting person.
  • Issuer identified: Pasithea Therapeutics Corp., with common stock par value $0.0001 per share and CUSIP 70261F202, is the subject company.
  • Triggering event date: September 30, 2026 is listed as the date of the event requiring the filing.
  • Item 5 classification: The filing notes ownership of 5 percent or less of a class.

Opaleye Group Reports Full Exit From Pasithea Therapeutics Holdings

According to the filing, Opaleye Management Inc., identified as an investment adviser incorporated in Massachusetts, and its affiliated fund Opaleye, L.P., a Delaware limited partnership, along with James Silverman, President of Opaleye Management Inc. and Managing Member of Opaleye GP LLC, submitted Amendment No. 2 to their prior beneficial ownership statement. The filing states that "as of September 30, 2026, none of the Reporting Persons beneficially owned any shares of Common Stock of the Issuer." Pasithea Therapeutics Corp. is a clinical-stage biopharmaceutical company whose common stock carries a par value of $0.0001 per share and is identified by CUSIP number 70261F202.

The filing reports that for each of the three reporting persons, sole voting power, shared voting power, sole dispositive power, and shared dispositive power all stand at 0.00. The aggregate amount beneficially owned by each reporting person is likewise listed as 0, representing 0% of the class. The business address for the reporting persons is listed as One Boston Place, 26th Floor, Boston, MA 02108, while Pasithea Therapeutics Corp.'s principal executive offices are located at 830 Winter Street, Waltham, MA 02451, according to the filing.

The statement was signed by James Silverman on November 6, 2026, in his capacity as President of Opaleye Management Inc., as Managing Member of Opaleye GP LLC (general partner of Opaleye, L.P.), and individually. The filing includes Exhibit 99.1, described as a Joint Filing Agreement among the reporting persons. The certifications in the filing state that the securities were not acquired or held for the purpose of changing or influencing control of the issuer.

What Was Disclosed

Opaleye Management Inc., Opaleye, L.P., and James Silverman disclosed through Amendment No. 2 that they held zero shares of Pasithea Therapeutics Corp. common stock as of September 30, 2026, with no voting or dispositive power over any shares of the issuer.